Compass Pathways (Nasdaq: CMPS) this morning announced that it will be launching the phase II clinical trial for its synthetic psilocybin compound known as COMP360. The trial aims to assess the safety and tolerability of psilocybin therapy in treating post-traumatic stress disorder.
COMP360 is the firm’s proprietary formulation of synthetic psilocybin currently being developed for treatment-resistant depression.
The multicentre, open-label trial will enroll 20 participants and will focus on the safety and tolerability of psilocybin therapy in people with PTSD stemming from trauma experienced as an adult. Participants will receive a single 25mg dose of COMP360, combined with psychological support and therapy protocols, and will be followed up for 12 weeks.
Sponsored · Cambria Gold Mines
“We have made great progress in developing COMP360 psilocybin therapy for patients suffering [from] treatment-resistant depression, and are pleased to be able to expand development into the indication of PTSD, another area of significant unmet need. As many as one in 20 people in the UK suffer [from] PTSD and up to 40% of those are not helped by existing treatments,” said Compass Pathways CEO George Goldsmith.
The study is set to commence at The Institute of Psychiatry, Psychology & Neuroscience at King’s College London.
Compass Pathways last traded at US$44.86 on the Nasdaq.
Information for this briefing was found via Edgar and Compass Pathways. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
